Vanguard Group
CMPX icon

Vanguard Group’s Compass Therapeutics CMPX Stock Holding History

Vanguard Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$43.2M Buy
8,048,374
+985,575
+14% +$4.55M ﹤0.01% 2241
2025
Q3 		$24.7M Buy
7,062,799
+2,212,794
+46% +$6.99M ﹤0.01% 2525
2025
Q2 		$12.6M Buy
4,850,005
+11,999
+0.2% +$24.7K ﹤0.01% 2785
2025
Q1 		$9.19M Buy
4,838,006
+119,812
+3% +$319K ﹤0.01% 2893
2024
Q4 		$6.84M Buy
4,718,194
+435,008
+10% +$722K ﹤0.01% 3135
2024
Q3 		$7.88M Buy
4,283,186
+90,657
+2% +$113K ﹤0.01% 3074
2024
Q2 		$4.19M Buy
4,192,529
+40,332
+1% +$58.9K ﹤0.01% 3327
2024
Q1 		$8.22M Buy
4,152,197
+71,008
+2% +$123K ﹤0.01% 3070
2023
Q4 		$6.37M Sell
4,081,189
-26,330
-0.6% -$45.6K ﹤0.01% 3188
2023
Q3 		$8.09M Buy
4,107,519
+9,637
+0.2% +$23.8K ﹤0.01% 3004
2023
Q2 		$13M Buy
4,097,882
+408,556
+11% +$1.28M ﹤0.01% 2800
2023
Q1 		$12.1M Buy
3,689,326
+78,922
+2% +$310K ﹤0.01% 2838
2022
Q4 		$18.2M Buy
3,610,404
+1,229,781
+52% +$4.9M ﹤0.01% 2665
2022
Q3 		$5.43M Buy
2,380,623
+878,650
+58% +$2.43M ﹤0.01% 3284
2022
Q2 		$3.98M Sell
1,501,973
-70,909
-5% -$154K ﹤0.01% 3498
2022
Q1 		$2.15M Hold
1,572,882
– – ﹤0.01% 3924
2021
Q4 		$4.99M Buy
+1,572,882
New +$5.22M ﹤0.01% 3606

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group's CMPX Position: Q4 2025 in Review

Vanguard Group increased its Compass Therapeutics (CMPX) stake by 14% in Q4 2025, buying an estimated $4.55M and bringing the position to 8,048,374 shares worth $43.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

Vanguard Group first reported a position in CMPX in Q4 2021 and has held it in 17 quarters since. 173 funds tracked by Wall St. Rank hold CMPX as of Q4 2025.

  • Vanguard Group held 8,048,374 shares of Compass Therapeutics worth $43.2M as of Q4 2025.
  • Vanguard Group bought 985,575 Compass Therapeutics shares in Q4 2025, an estimated $4.55M.
  • Compass Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2241 holding.
  • Vanguard Group first reported a position in Compass Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 173 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.